UROGENESYS ANNOUNCES U.S. PATENT FOR PROSTATE SPECIFIC ANTIGEN(PSA) PROMOTER SEQUENCES AND THEIR USES IN GENE THERAPY Santa Monica, Calif., August 30, 1999 - UroGenesys, Inc. announced today that the U.S. Patent Office has issued a patent to the University of California Los Angeles, for promoter sequences of the human Prostate Specific Antigen (PSA), and their uses for gene therapy applications in prostate cancer.The patent is licensed exclusively to UroGenesys. The patent co-inventors are Arie Belldegrun, M.D., and Shen Pang, Ph.D., both from the UCLA School of Medicine.Dr. Belldegrun is a Founder of UroGenesys and Chairman of its Board of Directors. The patent (No. 5,919,652) claims sequences that regulate the specific expression of PSA in the prostate, in conjunction with multiple enhancer elements.It also covers their utilization to direct high and specific expression of therapeutic genes in the prostate for treatment of prostate cancer or other disorders of the prostate gland. UroGenesys President and CEO Donald B. Rice commented, "The issuance of this patent further expands our intellectual property in the field of prostate cancer, which includes numerous patent applications on novel antigen targets discovered by the Company as well as others licensed exclusively from UCLA." UroGenesys, Inc. is a privately held, early stage biotechnology company whose purpose is development of improved therapeutic and diagnostic products for urological cancers, with an initial emphasis on prostate cancer.The Company is focused on validating its novel clinically relevant targets and seeking corporate collaborations for their product development. For more information about UroGenesys, see http://www.urogenesys.com/. Contacts Donald Rice, Ph.D. President and CEO drice@urogenesys.com Aya Jakobovits, Ph.D. Vice President of Research; Chief Scientific Officer ajakobovits@urogenesys.com